Infections in Diabetes Mellitus and Hyperglycemia

Infectious Disease Clinics of North America

Volumn 21, Issue 3, 2007, Pages 617-638

  Gupta, Smita ^a   Koirala, Janak ^a   Khardori, Romesh ^a   Khardori, Nancy ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOROLFINE; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; AMPICILLIN; ANTIINFECTIVE AGENT; BIFONAZOLE; CEFTRIAXONE; CICLOPIROX; CIPROFLOXACIN; CLINDAMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; DEFEROXAMINE; ECHINOCANDIN; FLUCONAZOLE; GENTAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRISEOFULVIN; IMMUNOSUPPRESSIVE AGENT; ISONIAZID; ITRACONAZOLE; METRONIDAZOLE; ORAL ANTIDIABETIC AGENT; POSACONAZOLE; PYRIDOXINE; RIFAMPICIN; TERBINAFINE; UREA; VORICONAZOLE;

ADAPTIVE IMMUNITY; ANTIMICROBIAL THERAPY; CHEMOTAXIS; CYSTITIS; DIABETES MELLITUS; DIABETIC FOOT; DIABETIC PATIENT; DRUG DOSE INCREASE; EMPHYSEMATOUS CHOLECYSTITIS; EXTERNAL OTITIS; GLYCEMIC CONTROL; HIGH RISK POPULATION; HUMAN; HUMORAL IMMUNITY; HYPERGLYCEMIA; HYPOGLYCEMIA; INFECTION; INNATE IMMUNITY; MUCORMYCOSIS; PATHOGENESIS; PERIODONTAL DISEASE; PERIPHERAL NEUROPATHY; PHAGOCYTOSIS; PSOAS ABSCESS; PYELONEPHRITIS; RESPIRATORY TRACT INFECTION; REVIEW; SKIN INFECTION; STRESS; URINARY TRACT INFECTION;

DIABETES MELLITUS; HUMANS; HYPERGLYCEMIA; INFECTION;

EID: 34548443400     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2007.07.003     Document Type: Review

References (133)

1. Van den Berghe G., Wouters P., Weekers F., et al. Intensive insulin therapy in critically ill patients. N Engl J Med 345 (2001) 1359-1367
2. Furnary A.P., and Wu Y. Eliminating the diabetic disadvantage: the Portland Diabetes Project. Semin Thorac Cardiovasc Surg 184 (2006) 302-308
3. Bouche C., Serdy S., Kahn C.R., et al. The cellular fate of glucose and its relevance in type 2 diabetes. Endocr Rev 25 (2004) 807-830
4. Borrengaard N., and Herlin T. Energy metabolism of human neutrophils during phagocytosis. J Clin invest 70 (1982) 550-557
5. Kim S.H., Park K.W., and Kim Y.S. Effects of acute hyperglycemia on endothelium-dependent vasodilation in patients with diabetes mellitus or impaired glucose metabolism. Endothelium 10 (2003) 65-70
6. Santilli F., Cipollone F., and Mezzetti A. The role of nitric oxide in the development of diabetic angiopathy. Horm Metab Res 36 (2004) 319-335
7. Schiekofer S., Balletshofer B., and Andrassy M. Endothelial dysfunction in diabetes mellitus. Semin Thromb Hemost 26 (2000) 503-511
8. Sampson M.J., Davies I.R., and Brown J.C. Monocyte and neutrophil adhesion molecule expression during acute hyperglycemia and after antioxidant treatment in type 2 diabetes and control patients. Arterioscler Thromb Vasc Biol 22 (2002) 1187-1193
9. Altannavch T.S., Roubalova K., and Kucera P. Effect of high glucose concentrations on expression of ELAM-1, VCAM-1 and ICAM-1 in HUVEC with and without cytokine activation. Physiol Res 53 (2004) 77-82
10. Kado S., Wakatsuki T., and Yamamoto M. Expression of intercellular adhesion molecule-1 induced by high glucose concentrations in human aortic endothelial cells. Life Sci 68 (2001) 727-737
11. Morigi M., Angioletti S., and Imberti B. Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion. J Clin Invest 10 (1998) 1905-1915
12. Bergamaschini L., Gardinali M., Ploi M., et al. Complement activation in diabetes. J Clin Lab Immunol 353 (1991) 121-127
13. Saiepour D., Sehlin J., and Oldenborg P.A. Hyperglycemia-induced protein kinase C activation inhibits phagocytosis of C3b- and immunoglobulin g-opsonized yeast particles in normal human neutrophils. Exp Diabesity Res 4 (2003) 125-132
14. Saipour D., Sehlin J., and Oldenborg P.-A. Insulin inhibits phagocytosis in normal human neutrophils via PKCά/β-dependent priming of F-actin assembly. Inflamm Res 55 (2006) 85-91
15. Turina M., Fry D., and Polk H.C. Acute hyperglycemia and innate immune system: clinical, cellular and molecular aspects. Crit Care Med 337 (2005) 1624-1633
16. Walrand S., Guillet C., Boirie Y., et al. In vivo evidence that insulin regulates human polymorphonuclear neutrophil functions. J Leukoc Biol 766 (2004) 1104-1110
17. Mowat A., and Baum J. Chemotaxis of polymorphonuclear leukocytes from patients with diabetes mellitus. N Engl J Med 284 (1971) 621-627
18. Geerlings S.E., and Hoepelman A.I. Immune dysfunction in patients with diabetes mellitus DM. FEMS Immunol Med Microbiol 26 (1999) 259-265
19. Delamaire M., Maugendre D., and Moreno M. Impaired leucocyte functions in diabetic patients. Diabet Med 14 (1997) 29-34
20. Cavalot F., Anfossi G., and Russo I. Insulin at physiological concentrations, enhances the polymorphonuclear leukocyte chemotactic properties. Horm Metab Res 24 (1992) 225-228
21. Wierusz-Wysocka B., Wysocki H., and Wykretowicz A. The influence of increasing glucose concentrations on selected functions of polymorphonuclear neutrophils. Acta Diabetol Lat 25 (1988) 283-288
22. Alexiewicz J.M., Kumar D., and Smogorzewski M. Polymorphonuclear leukocytes in non-insulin-dependent diabetes mellitus: abnormalities in metabolism and function. Ann Intern Med 12 (1995) 919-924
23. Marhoffer W., Stein M., and Maeser E. Impairment of polymorphonuclear leukocyte function and metabolic control of diabetes. Diabetes Care 15 (1992) 256-260
24. Wilson R.M., and Reeves W.G. Neutrophil phagocytosis and killing in insulin-dependent diabetes. Clin Exp Immunol 63 (1986) 478-484
25. Perner A., Nielsen S.E., and Rask-Madsen J. High glucose impairs superoxide production from isolated blood neutrophils. Intensive Care Med 29 (2003) 642-645
26. Mohanty P., Hamouda W., and Garg R. Glucose challenge stimulates reactive oxygen species ROS generation by leucocytes. J Clin Endocrinol Metab 85 (2000) 2970-2973
27. Sato N., Kashima K., and Shimizu H. Hypertonic glucose impairs glucose-induced increases in cytosol Ca2+ concentration and insulin secretion by HIT-T 15 cells. Cell Calcium 20 (1996) 273-278
28. Catalan M.P., Reyero A., and Egido J. Acceleration of neutrophil apoptosis by glucose-containing peritoneal dialysis solutions: role of caspases. J Am Soc Nephrol 12 (2001) 2442-2449
29. Tennenberg S.D., Finkenauer R., and Dwivedi A. Absence of lipopolysaccharide-induced inhibition of neutrophil apoptosis in patients with diabetes. Arch Surg 134 (1999) 1229-1233
30. Sato N., Kashima K., Uehara Y., et al. Epalrestat, an aldose reductase inhibitor, improves impaired generation of oxygen derived free radicals by neutrophils from poorly controlled NIDDM patients. Diabetes 46 (1997) 133-137
31. Gough A., Clapperton M., Rolando N., et al. Randomized placebo controlled trial of granulocyte colony stimulating factor in diabetic foot infections. Lancet 20 (1997) 995-998
32. Yonem A., Cakir B., Buler S., et al. Effects of granulocyte colony stimulating factor in treatment of diabetic foot infections. Diabetes Obes Metab 3 (2001) 332-337
33. MacCuish A.C., Urbaniak S.J., Campbell C.J., et al. Phytohemagglutinin transformation and circulating lymphocyte populations in insulin-dependent diabetic patients. Diabetes 23 (1974) 78-712
34. Pozzilli P., Pagani S., Arduini P., et al. In vivo determination of cell mediated immune response in diabetic patients using multiple intradermal antigen dispenser. Diabetes Res 6 (1987) 5-8
35. Peleg A.Y., Weerarathna T., McCarthy J.S., et al. Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes Metab Res Rev 231 (2007) 3-13
36. Lapolla A., Tonani R., Fedele D., et al. Non enzymatic glycation of IgG: an in vivo study. Horm Metab Res 34 (2002) 260-264
37. Jackson L.A. Evlauating diabetes mellitus as risk factor for community acquired infections. Clin Infect Dis 41 (2005) 289-290
38. Muller L.M.A.J., Gorter K.J., Hak E., et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis 41 (2005) 281-288
39. Zhanel C.G., Harding G.K.M., and Nicolle L.E. Asymptomatic bacteriuria in patients with diabetes mellitus. Rev Infect Dis 13 (1991) 150-154
40. Fortland M., Thomas V., and Shekolov A. Urinary tract infections in patients with diabetes mellitus. JAMA 238 (1977) 1924-1926
41. Geerlings S.E., Stolk R.P., Camps M.J.L., et al. Asymptomatic bacteriuria may be considered a complication in women with diabetes. Diabetes Mellitus Women Asymptomatic Bacteriuria Utrecht Study Group. Diabetes Care 236 (2000) 744-749
42. Geerlings S.E., Stolk R.P., Camp M.J., et al. Consequences of asymptomatic bacteriuria in women with diabetes mellitus. Arch Intern Med 161 11 (2001) 1421-1427
43. Karunajeewa H., Mc Gechie D., Stuccio G., et al. Asymptomatic bacteriuria as a predictor of subsequent hospitalisation with urinary tract infection in diabetic adults: The Fremantle Diabetes Study. Diabetologia 487 (2005) 1288-1291
44. Meiland R., Geerlings S.E., Stolk R.P., et al. Asymptomatic bacteriuria in women with diabetes mellitus: effect on renal function after 6 years of follow-up. Arch Intern Med 166 20 (2006) 2222-2227
45. Geerlings S.E., Meiland R., and Hoepelman A.I. Pathogenesis of bacteriuria in women with diabetes mellitus. Int J Antimicrob Agents 196 (2002) 539-545
46. Meiland R., Geerlings S.E., De Neeling A.J., et al. Diabetes mellitus in itself is not a risk factor for antibiotic resistance in Escherichia coli isolated from patients with bacteriuria. Diabet Med 21 (2004) 1032-1034
47. Ooi S.T., Frazee L.A., and Gardner W.G. Management of asymptomatic bacteriuria in patients with diabetes mellitus. Ann Pharmacother 38 3 (2004) 490-493
48. Nicolle L.E., Bradley S., Colgan R., et al. Infectious Diseases Society of America; American Society of Nephrology; American Geriatric Society. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis 40 (2005) 643-654
49. Patterson J.E., and Andriole V.T. Bacterial urinary tract infections in diabetes. Inf Dis Clin North Am 9 (1995) 25-51
50. Hoepelman A.I., Meiland R., and Geerlings S.E. Pathogenesis and management of bacterial urinary tract infections in adult patients with diabetes mellitus. Int J Antimicrob Agents 22 Suppl 2 (2003) 35-43
51. Strevel E., Kuper A., and Gold W.L. Severe and protracted hypoglycemia associated with co-trimoxazole use. Lancet Infect Dis 6 (2006) 178-182
52. Horcajada J.P., Moreno I., Velasco M., et al. Community-acquired febrile urinary tract infection in diabetics could deserve a different management: a case-control study. J Intern Med 254 (2003) 280-286
53. Hsia C.C.W., and Raskin P. The diabetic lung: relevance of alveola rmicroangiopathy to the use of inhaled insulin. The Am J Med 118 (2005) 205-211
54. Nicolaie T., Zavoianu C., and Nuta P. Pulmonary involvement in diabetes mellitus. Rom J Intern Med 414 (2003) 365-374
55. Marvisi M., Marani G., Brianti M., et al. Pulmonary complications in diabetes mellitus. Recenti Prog Med 8712 (1996) 623-627
56. Philips B.J., Redman J., Brennan A., et al. Glucose in bronchial aspirates increases the risk of respiratory MRSA in intubated patients. Thorax 60 (2005) 761-764
57. Ruiz M., Ewig S., Marcos M.A., et al. Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. Am J Respir Crit Care Med 160 2 (1999) 397-405
58. Thomsen R.W., Hundborg H.H., Lervang H.H., et al. Risk of community-acquired pneumococcal bacteremia in patients with diabetes: a population-based case-control study. Diabetes Care 275 (2004) 1143-1147
59. Jabbar A., Hussain S.F., and Khan A.A. Clinical characteristics of pulmonary tuberculosis in adult Pakistani patients with co-existing diabetes mellitus. East Mediterr Health J 125 (2006) 522-527
60. Feleke Y., Abdulkadir J., and Aderaye G. Prevalence and clinical features of tuberculosis in Ethiopian diabetic patients. East Afr Med J 767 (1999) 361-364
61. Pablos-Méndez A., Blustein J., and Knirsch C.A. The role of diabetes mellitus in the higher prevalence of tuberculosis among Hispanics. Am J Public Health 87 4 (1997) 574-579
62. Ponce-De-Leon A., Garcia-Garcia M.L., Garcia-Sancho M.C., et al. Tuberculosis and diabetes in southern Mexico. Diabetes Care 27 (2004) 1584-1590
63. Perez-Guzman C., Torres-Cruz A., Villarreal-Velarde H., et al. Progressive age-related changes in pulmonary tuberculosis images and the effect of diabetes. Am J Respir Crit Care Med 162 (2000) 1738-1740
64. Bashar M., Alcabes P., Rom W.N., et al. Increased incidence of multidrug-resistant tuberculosis in diabetic patients on the Bellevue Chest Service, 1987 to 1997. Chest 120 (2001) 1514-1519
65. Singla R., and Khan N. Does diabetes predispose to the development of multidrug-resistant tuberculosis?. Chest 123 (2003) 308-309
66. API Consensus Expert Committee. API TB Consensus Guidelines 2006: management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations. J Assoc Physicians India 54 (2006) 219-234
67. Broxmeyer L. Diabetes mellitus, tuberculosis and the mycobacteria: two millennia of enigma. Med Hypotheses 65 (2005) 433-439
68. Rosenstein N.E., Emery K.W., Werner S.B., et al. Risk factors for severe pulmonary and disseminated coccidioidomycosis: Kern County, California, 1995-1996. Clin Infect Dis 32 (2001) 708-715
69. Santelli A.C., Blair J.E., and Roust L.R. Coccidioidomycosis in patients with diabetes mellitus. Am J Med 11911 (2006) 964-969
70. Loe H. Periodontal disease: the sixth complication of diabetes. Diabetes Care 16 (1993) 329-334
71. Lalla E., Cheng B., Lal S., et al. Periodontal changes in children and adolescents with diabetes: a case-control study. Diabetes Care 29 (2006) 295-299
72. Meng H.X. Association between periodontitis and diabetes mellitus. Beijing Da Xue Xue Bao 391 (2007) 18-20
73. Lalla E., Lamster I.B., Feit M., et al. Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice. J Clin Invest 105 (2000) 1117-1124
74. Iacopino A.M. Periodontitis and diabetes interrelationships. Ann Periodontol 61 (2001) 125-137
75. Ojima M., Takeda M., Yoshioka H., et al. Relationship of periodontal bacterium genotypic variations with periodontitis in type 2 diabetic patients. Diabetes Care 28 (2005) 433-434
76. Pihlstrom B.L., Michalowicz B.S., and Johnson N.W. Periodontal diseases. Lancet 366 9499 (2005) 1809-1820
77. Slots J. Systemic antibiotics in periodontics. J Periodontol 75 (2004) 1553-1565
78. Wolfsthal S.D. Emergencies in diabetic patients in the primary care setting. Prim Care 333 (2006) 711-725
79. Tan J.S., and Joseph W.S. Common fungal infections of the feet in patents with diabetes mellitus. Drugs Aging 212 (2004) 101-112
80. Robbins J.M. Treatment of onychomycosis in the diabetic patient population. J Diabetes Complications 172 (2003) 98-104
81. Arenas R., Fernandez G., and Dominguez L. Onychomycosis treated with itraconazole or griseofulvin alone with and without a topical antimycotic or keratolytic agent. Int J Dermatol 308 (1991) 586-589
82. Faergemann J., Anderson C., Hersle K., et al. A double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. J Am Acad Dermatol 325 1 (1995) 750-753
83. Scher R.K. Onychomycosis: therapeutic update. J Am Acad Dermatol 406 2 (1999) S21-S26
84. Guggenheimer J., Moore P.A., Rossie K., et al. Insulin-dependent diabetes mellitus and oral soft tissue pathologies: II. Prevalence and characteristics of candida and candidal lesions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 895 (2000) 570-576
85. Lipsky B.A., Berendt A.R., Deery H.G., et al. Diagnosis and treatment of diabetic foot infections. IDSA Guidelines Committee on Diabetic Foot Infections. Clin Infect Dis 39 (2004) 885-910
86. Shank C.F., and Feibel J.B. Osteomyelitis in the diabetic foot: diagnosis and management. Foot Ankle Clin 114 (2006) 775-789
87. International Working Group on the Diabetic Foot. International consensus on the diabetic foot (2003), International Diabetes Foundation, Brussels
88. Rao N., and Lipsky B.A. Optimising antimicrobial therapy in diabetic foot infections. Drugs 67 2 (2007) 195-214
89. Lipsky B.A., and Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother 55 2 (2005) 240-245
90. Cruciani M., Lipsky B.A., Mengoli C., et al. Are granulocyte colony-stimulating factors beneficial in treating diabetic foot infections? A meta-analysis. Diabetes Care 282 (2005) 454-460
91. Senior C. Treatment of diabetic foot ulcers with hyperbaric oxygen. J Wound Care 94 (2000) 193-197
92. Kalani M., Jorneskog G., Naderi N., et al. Hyperbaric oxygen HBO therapy in treatment of diabetic foot ulcers: long term follow up. J Diabetes Complications 162 (2002) 153-158
93. Kessler L., Bilbault P., and Ortega F. Hyperbaric oxygenation accelerates the healing rate of nonischemic chronic diabetic foot ulcers: a prospective randomized study. Diabetes Care 268 (2003) 2378-2382
94. Dinh T.L., and Veves A. Treatment of diabetic ulcers. Dermatol Ther 19 (2006) 348-355
95. Mann R.J., and Peacock P.M. Hand infections in patients with diabetes mellitus. J Trauma 17 (1977) 376-380
96. Abbas Z.G., Lutale J., Archibald L.K., et al. Tropical diabetic hand syndrome Centers for Disease control and prevention. MMWR 51 43 (Nov 2002) 969-970
97. Bhansali A., Bhadada S., Sharma A., et al. Presentation and outcome of rhino-orbito-cerebral mucomycosis in patients with diabetes. Postgrad Med J 80949 (2004) 670-674
98. Yohai R.A., Bullock J.D., Aziz A.A., et al. Survival factors in rhino-orbital-cerebral mucormycosis: major review. Surv Ophthalmol 39 (1994) 3-22
99. Pillsbury H.C., and Fischer N.D. Rhinocerebral mucormycosis. Arch Otolaryngol 103 (1977) 600-604
100. Abramson E., Wilson D., and Arky R.A. Rhinocerebral phycomycosis in association with diabetic ketoacidosis. Ann Intern Med 66 4 (1967) 735-742
101. Perfect J.R. Treatment of non-aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin Infect Dis 40 Suppl 6 (2005) S401-S408
102. Kajs-Wyllie M. Hyperbaric oxygen therapy for rhinocerebral fungal infection. J Neurosci Nurs 273 (1995) 174-181
103. Rubin J., and Yu V.L. Malignant external otitis: insights into pathogenesis, clinical manifestations, diagnosis, and therapy. Am J Med 85 (1988) 391-398
104. Rubin Grandis J. The changing face of malignant necrotising external otitis: clinical, radiological, and anatomic correlations. Lancet Infect Dis 41 (2004) 34-39
105. Joshi N., Caputo G.M., Weitekamp M.R., et al. Primary care: infections in patients with diabetes. N Engl J Med 341 (1999) 1906-1912
106. Handzel O., and Halperin D. Necrotizing malignant external otitis. Am Fam Physician 682 (2003) 309-312
107. Franco-Vidal V., Blanchet H., Bebear C., et al. Necrotizing external otitis: a report of 46 cases. Otol Neurotol (2007) (epub ahead of print)
108. Bernstein J.M., Holland N.J., Porter G.C., et al. Resistance of Pseudomonas to ciprofloxacin: implications for the treatment of malignant otitis externa. J Laryngol Otol 121 2 (2007) 118-123
109. Berenholz L., Katzenell U., and Harell M. Evolving resistant pseudomonas to ciprofloxacin in malignant otitis externa. Laryngoscope 112 (2002) 1619-1622
110. Levenson M.J., Parisier S.C., Dolitsky J., et al. Ciprofloxacin: drug of choice in the treatment of malignant external otitis MEO. Laryngoscope 101 (1991) 821-824
111. Mader J.T., and Love J.T. Malignant external otitis: cure with adjunctive hyperbaric oxygen therapy. Arch Otolaryngol 108 (1982) 38-40
112. Davis J.C., Gates G.A., Lerner C., et al. Adjuvant hyperbaric oxygen in malignant external otitis. Arch Otolaryngol Head Neck Surg 118 (1992) 89-93
113. Oblak M.R., Oblak C., and Stankovic S. Psoas and spinal epidural abscess in a diabetic patient-case report. Diabetes Res Clin Pract 68 3 (2005) 274-277
114. Rajbhandari S.M., and Wilson R.M. Unusual infections in diabetes. Diabetes Res Clin Pract 39 2 (1998) 123-128
115. van den Berge M., de Marie S., Kuipers T., et al. Psoas abscess: report of a series and review of the literature. Neth J Med 63 10 (2005) 413-416
116. Garcia-Sancho Tellez L., Rodriguez-Montes J.A., Fernandez de Lis S., et al. Acute emphysematous cholecystitis. Report of twenty cases. Hepatogastroenterology 46 28 (1999) 2144-2148
117. Grupper M., Krastov A., and Potasman I. Emphysematous cystitis: illustrative case report and review of the literature. Medicine 86 (2007) 47-53
118. Thomas A.A., Lane B.R., Thomas A.Z., et al. Emphysematous cystitis: a review of 135 cases. BJU Int 100 (2007) 17-20
119. Kelly H.A., and MacCallum W.G. Pneumaturia. JAMA 31 (1898) 375-381
120. Michaeli J., Mogle P., Perlberg S., et al. Emphysematous pyelonephritis. J Urol 131 (1984) 203-208
121. Huang J.-J., and Tseng C.-C. Emphysematous pyelonephritis. Arch Intern Med 160 (2000) 797-805
122. Karasavidou L., Nikolaou S., Archontakis S., et al. Nonsurgical treatment of bilateral emphysematous pyelonephritis in a diabetic patient. J Nephrol 195 (2006) 664-667
123. Wang J.M., Lim H.K., and Pang K.K. Emphysematous pyelonephritis. Scand J Urol Nephrol 41 3 (2007) 223-229
124. Ketata H., Debre B., and Peyromaure M. Bilateral pyelonephritis and emphysematous cystitis: an exceptional association. Prog Urol 16 4 (2006) 493-495
125. Winsett O.E., and Wolma F.J. Complications of vascular access for hemodialysis. South Med J 78 (1985) 513-517
126. Amair P., Khanna R., Leibel B., et al. Continuous ambulatory peritoneal dialysis in diabetics with end stage renal disease. N Engl J Med 306 (1982) 625-630
127. Rajgopalan S. Serious infections in elderly patients with diabetes mellitus. Clin Infect Dis 40 (2005) 990-996
128. Memmel H., Kowal-Vern A., and Latenser B.A. Infections in diabetic burn patients. Diabetes Care 27 (2004) 229-233
129. Furnary A.P., Zerr K.G., Grunkemeier G.L., et al. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg 67 (1999) 352-60; discussion 360-2
130. Hiramatsu N., Kasai A., Hayakawa K., et al. Real-time detection and continuous monitoring of ER stress in vitro and in vivo by ES-TRAP evidence for systemic, transient ER stress during endotoxemia. Nucl Acid Res 34 (2006) e93
131. Tsiotra P., and Tsigos A. Stress, the endoplasmic reticulum, and insulin resistance. Ann NY Acad Sci 1083 (2006) 63-76
132. Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44 Suppl 2 (2007) S27-S72
133. Morpurgo E., and Galandiuk S. Fournier's gangrene. Surg Clin North Am 82 6 (2002) 1213-1224